Overview Dividends

(ICLR) ICON - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE0005711209

Clinical Trial Services, Laboratory Testing, Regulatory Consulting, Commercialization Support

ICLR EPS (Earnings per Share)

EPS Growth (3Y CAGR): 2.05%
EPS Trend (3Y Correlation): 38.9%

ICLR Revenue

Revenue Growth (3Y CAGR): 1.48%
Revenue Trend (3Y Correlation): 27.6%

Description: ICLR ICON October 31, 2025

ICON Public Limited (NASDAQ: ICLR) is a Dublin-based contract research organization that delivers end-to-end outsourced development and commercialization services for pharma, biotech, and medical-device clients across Europe, the United States, and globally. Its portfolio spans the full clinical-trial lifecycle-from early-stage compound selection through Phase I-IV studies, peri- and post-approval data solutions, and decentralized/hybrid trial execution-plus laboratory, biomarker, vaccine, and GMP manufacturing capabilities.

In FY 2023 the company reported revenue of roughly **$2.9 billion**, a **~9 % year-over-year increase** driven primarily by higher demand for decentralized trial platforms and a growing backlog of multi-phase studies. Operating margin hovered around **10 %**, reflecting continued investment in digital trial infrastructure. The global CRO market is projected to grow at a **CAGR of 7 % through 2028**, propelled by rising R&D spend in the biotech sector, tighter timelines for drug approvals, and regulatory incentives for real-world evidence-factors that underpin ICON’s growth outlook.

For a deeper, data-driven valuation of ICON, you might explore the analytics on ValueRay, which aggregates peer-adjusted multiples and cash-flow forecasts to help assess the company’s relative upside.

ICLR Stock Overview

Market Cap in USD	12,889m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	1998-05-15

ICLR Stock Ratings

Growth Rating	-42.9%
Fundamental	52.6%
Dividend Rating	-
Return 12m vs S&P 500	-37.7%
Analyst Rating	4.29 of 5

ICLR Dividends

Currently no dividends paid

ICLR Growth Ratios

Growth Correlation 3m	12.4%
Growth Correlation 12m	-53.3%
Growth Correlation 5y	-11.1%
CAGR 5y	-9.63%
CAGR/Max DD 3y (Calmar Ratio)	-0.15
CAGR/Mean DD 3y (Pain Ratio)	-0.44
Sharpe Ratio 12m	-1.12
Alpha	-49.35
Beta	1.229
Volatility	47.30%
Current Volume	570.3k
Average Volume 20d	898.5k
Stop Loss	150.5 (-5.9%)
Signal	-0.49

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (599.5m TTM) > 0 and > 6% of Revenue (6% = 486.2m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -1.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.34% (prev 11.56%; Δ -9.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.18b > Net Income 599.5m (YES >=105%, WARN >=100%)

Net Debt (3.10b) to EBITDA (1.18b) ratio: 2.63 <= 3.0 (WARN <= 3.5)

Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (78.1m) change vs 12m ago -6.43% (target <= -2.0% for YES)

Gross Margin 26.85% (prev 29.58%; Δ -2.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 48.06% (prev 48.26%; Δ -0.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.96 (EBITDA TTM 1.18b / Interest Expense TTM 199.4m) >= 6 (WARN >= 3)

Altman Z'' 1.17

(A) 0.01 = (Total Current Assets 3.41b - Total Current Liabilities 3.22b) / Total Assets 16.51b

(B) 0.14 = Retained Earnings (Balance) 2.31b / Total Assets 16.51b

(D) 0.31 = Book Value of Equity 2.23b / Total Liabilities 7.17b

Total Rating: 1.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 52.59

1. Piotroski 5.50pt = 0.50

2. FCF Yield 6.23% = 3.11

3. FCF Margin 12.29% = 3.07

4. Debt/Equity 0.38 = 2.43

5. Debt/Ebitda 2.63 = -1.19

6. ROIC - WACC (= -7.89)% = -9.87

7. RoE 6.32% = 0.53

8. Rev. Trend 27.57% = 2.07

9. EPS Trend 38.90% = 1.94

What is the price of ICLR shares?

As of November 07, 2025, the stock is trading at USD 160.00 with a total of 570,265 shares traded.
Over the past week, the price has changed by -3.22%, over one month by -15.98%, over three months by +2.95% and over the past year by -28.52%.

Is ICON a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, ICON is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 52.59 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ICLR is around 138.20 USD . This means that ICLR is currently overvalued and has a potential downside of -13.63%.

Is ICLR a buy, sell or hold?

ICON has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ICLR.

Strong Buy: 11
Buy: 0
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ICLR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	208.3	30.2%
Analysts Target Price	208.3	30.2%
ValueRay Target Price	153.8	-3.9%

ICLR Fundamental Data Overview November 05, 2025

Market Cap USD = 12.89b (12.89b USD * 1.0 USD.USD)
P/E Trailing = 22.7787
P/E Forward = 13.5318
P/S = 1.5907
P/B = 1.5706
P/EG = 1.3017
Beta = 1.229
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 3.40b USD (from longTermDebt, last fiscal year)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 15.99b USD (12.89b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
FCF Yield = 6.23% (FCF TTM 995.8m / Enterprise Value 15.99b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 0.97 (Enterprise Value 15.99b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 93.82% (35.7m / 38.1m)
NOPAT = 48.8m (EBIT 790.0m * (1 - 93.82%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.14% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 3.40b))
RoIC = 0.38% (NOPAT 48.8m / Invested Capital 12.95b)
WACC = 8.27% (E(12.89b)/V(16.46b) * Re(10.54%) + D(3.57b)/V(16.46b) * Rd(1.41%) * (1-Tc(0.94)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 67.61% ; FCFE base≈1.09b ; Y1≈980.1m ; Y5≈842.0m
Fair Price DCF = 135.0 (DCF Value 10.31b / Shares Outstanding 76.4m; 5y FCF grow -12.41% → 3.0% )
EPS Correlation: 38.90 | EPS CAGR: 2.05% | SUE: -0.05 | # QB: 0
Revenue Correlation: 27.57 | Revenue CAGR: 1.48% | SUE: 1.53 | # QB: 2

Additional Sources for ICLR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle